Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
|
|
- Clifton Frank Shelton
- 6 years ago
- Views:
Transcription
1 Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan (2003) 6, & 2003 Nature Publishing Group All rights reserved /03 $ We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group 1, n ¼ 12) and those with longer periods of AA (Group 2, n ¼ 26). Serial changes in hormones and prostate-specific antigen (PSA) were prospectively monitored following cessation of AA. The median durations of AA in the two groups were 8.5 and 54.5 months, respectively. Levels of total testosterone (T), luteinizing hormone and PSA increased significantly with time. At the end of 2 y, 30/38 patients (78.9%) had T levels above 50 ng/dl and 19/38 (50%) had levels above 320 ng/dl. Patients in Group 2 required significantly longer duration for T recovery. Complete T recovery is not always accompanied by rising PSA. Recovery of T levels is often slow following cessation of prolonged AA. Expression of PSA after AA is often variable and unpredictable. Thus, interpretation of outcomes in clinical trials incorporating AA needs caution and careful consideration. (2003) 6, doi: /sj.pcan Keywords: androgen ablation; testosterone; prostate-specific antigen; bone mineral density Introduction Since the introduction of endocrine therapy by Huggins and Hodges 1 in 1941, androgen ablation (AA) has been the mainstay for treatment of advanced prostate cancer treatment. Today, AA is used in multiple clinical settings that include intermittent hormonal therapy 2 4 and neoadjuvant or adjuvant therapy combined with definitive local treatment. 5 7 Use of luteinizing hormone releasing hormone agonists (LHRHa) has become the preferred method of AA. Knowledge of long-term outcome is important to assess critically the clinical impact of prolonged adjuvant therapy, and several important *Correspondence: S Egawa, Department of Urology, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa , Japan. s-egpro@jcom.home.ne.jp Received 10 January 2003; revised 10 May 2003; accepted 17 June 2003 observations have recently been made regarding the reversibility of LHRHa effects after cessation of AA. 6,8 11 The objectives of the present study are to characterize changes in levels of hormones and prostate-specific antigen (PSA) after withdrawal of AA in 38 Japanese patients with prostate cancer. Patients and methods Patients Between March 1999 and January 2002, 38 Japanese patients who had undergone AA for histologically confirmed prostate cancer were invited to join this study at Kitasato University Hospital. AA had been maintained with a combination of 1-month depot injection of LHRHa (leuprolide acetate 3.75 mg or goserelin acetate 3.6 mg) and antiandrogen (flutamide 375 mg/day) in 16 patients
2 246 and with LHRHa alone in 21 patients. One patient had been maintained on a daily dose of diethylstilbestrol diphosphate (DESD), 200 mg. The patient group included 29 men with advanced prostate cancer who were recruited for a prospective trial of intermittent endocrine therapy; 17 of these patients had multiple bone metastases. 2 These intermittent therapy patients had received at least 15 months of AA. All drugs were discontinued at the time of study entry and serial data were collected during the off-therapy period. Androgen ablation was resumed 2 months after PSA reached levels greater than 10 ng/ml, when indicated clinically, or on patient request. The study also included nine patients who underwent 8 or more months of neoadjuvant endocrine therapy prior to radical prostatectomy for resectable prostate cancer. No patient showed any evidence of clinical or biochemical progression during endocrine therapy. Before entering the study, all 38 patients gave signed informed consent after discussion. Study design and assessment In order to investigate the impact of length of AA, patients were further stratified into those whose AA duration was less than 24 months (Group 1, n ¼ 12) and those with longer duration AA (Group 2, n ¼ 26). Patients were seen in monthly follow-up visits to determine treatment-related side effects and to measure serum PSA, total testosterone (T) and luteinizing hormone (LH) levels. Blood samples were collected between 0900 and Serum PSA after withdrawal of AA was quantitated by an Immulite third-generation hypersensitive assay (Iatron Laboratories, Inc., Tokyo, Japan). Values prior to AA were measured by AxSYM assay (Dinabot, Tokyo, Japan). Total T and LH were measured by immunoradiometric assay. The normal ranges for T and LH in this study are ng/dl and miu/ml, respectively. Castrate serum T was defined as less than 50 ng/dl. Statistical analysis Differences between values at each time point were assessed by the Wilcoxon signed rank test, while other values were assessed using the Mann Whitney U or Kruskal Wallis test. Standard Kaplan Meier actuarial statistics were used to generate curves of T-level recovery, with the log-rank test being used to compare recovery of hormone values. The impact of covariates on recovery of T levels was assessed using multivariate logistic regression analysis. Covariates included age, clinical stage, pretreatment PSA, biopsy tumor grade, gland volume, total T levels prior to AA, and type and duration of endocrine therapy. P-values o0.05 were considered significant. Results Baseline clinical findings Table 1 shows patient demographics at entry and duration of follow-up. Table 2 shows baseline PSA, T and LH levels as well as serial changes between baseline and end of follow-up. Serum T levels prior to AA were available for 22 patients, with a median value of ng/ dl (range ). Five patients had subnormal T levels prior to treatment; values in three of these reached the normal range at some point during follow-up. Changes of hormone levels after withdrawal of AA Levels of T and LH increased significantly with time after cessation of AA (Table 2). Figure 1 illustrates the time course of T recovery in Groups 1 and 2, as well as in a subgroup of patients who had AA for 36 months or longer. Patients in both Group 2 subgroups required significantly longer duration for T recovery than those in Group 1. Within 2 years, T levels recovered above 50 ng/dl in 30 patients (78.9%), including 11 (92%) in Group 1 and 19 (73%) in Group 2; the respective median times to recovery were 2.0 (1 5) and 4.0 (1 36) months (P40.05). Normal T levels (4320 ng/dl) were achieved by 19 patients (50%), including 10 (83%) in Group 1 and nine (35%) in Group 2; respective median times to recovery were 3.0 (2 9) and 11.0 (2 19) months (Po0.01). For Group 2, the median T value at 6 months (33.0 ng/dl) was in the castrate range, but by 9 months had recovered slightly to ng/dl. Eight patients remained at castrate T levels after a median follow-up time of 27.0 (2 36) months. Recovery of T generally paralleled LH recovery. Six of seven patients who had castrate levels of T after months of follow-up had above-normal LH. In the remaining patient, who had undergone prolonged DES treatment, LH levels remained subnormal 19 months after AA discontinuation. Changes of PSA after withdrawal of AA Longer AA duration tended to delay the increase in PSA. While half (2/4) of the nonsurgical patients in Group 1 reached PSA levels of 10 ng/dl following discontinuation Table 1 Patient demographics Total (n=38) Group 1 (n=12) Group 2 (n=26) P-value Age at entry (y) (48 84) (52 81) (48 84) NS AA duration (months) (8 126) (8 23) (26 126) o Follow-up duration (months) (2 36) (2 35) (2 36) PSA prior to AA (ng/ml) ( ) ( ) ( ) NS Biopsy Gleason score (3 9) (3 8) (4 9) 0.04 AA, androgen ablation; PSA, prostate-specific antigen; s.e., standard error, NS, not significant.
3 Table 2 Changes in PSA and hormone levels after withdrawal of androgen ablation 247 Months after off Tx PSA (ng/ml) Total testosterone (ng/dl) LH (miu/ml) ( , 36) (5 89, 28) ( , 18) * ( , 30) * (5 276, 22) * ( , 14) ** ( , 28) ** (5 665, 26) ** ( , 14) ** ( , 29) ** (5 697, 23) ** (1 33.5, 15) ** ( , 22) ** (5 770, 16) * ( , 12) ** ( , 18) ** (5 453, 15) * ( , 9) ** ( , 12) * (5 481, 9) ( , 7) ** ( , 14) ** (8 624, 9) * (1 18.6, 8) * ( , 8) * (9 708, 6) ( , 4) ( , 6) (5 660, 5) ( , 4) ( , 3) (20 62, 3) ( , 3) PSA, prostate-specific antigen; LH, luteinizing hormone; Hb, hemoglobin; BMD, bone mineral density; Tx, endocrine therapy; s.e., standard error. *Po0.05, **Po0.01, vs baseline levels. The Values are expressed as median7s.e. (range, no. of patients). Figure 1 Recovery of total testosterone levels of 50 ng/ml or greater after withdrawal of AA for prostate cancer according to group stratification: T, total testosterone levels; o24m, patients who had undergone AA less than 24 months; X24M, patients who had undergone AA 24 months or longer; and X36M, patients who had undergone AA 36 months or longer. of therapy, only 36.0% (9/25) of those in Group 2 did so. All but one patient responded to resumption of AA. As shown in Figure 2a, b and Table 3, levels of T did not necessarily parallel PSA values. Of the 18 patients with subnormal T recovery, six (33.3%) reached PSA levels above 10.0 ng/ml, while in nine (50.0%) the PSA level remained below 1.0 ng/ml. Those who reached values of 10.0 ng/ml did so at a median time of 19.0 (2 30) months, while median follow-up in those with very low values was 33.0 (2 36) months. Of the 11 patients whose T recovered to normal levels, five (45.5%) reached PSA levels above 10.0 ng/ml (median time 11.0 (10 16) months), while in three (27.3%) the PSA remained below 1.0 ng/ml at a median follow-up time of 31.0 (30 34) months. Rising PSA was noted despite castrate levels of T in two patients. One of these appeared to be hormone resistant. Results of logistic regression multivariate analysis All parameters tested failed to predict the delayed recovery of T at any time point after withdrawal of AA (P40.05). Figure 2 Changes of PSA after withdrawal of AA: M, months. (a) Patients with subnormal recovery of total testosterone (o320 ng/dl). Figures in the graph indicate testosterone levels at the last observation (ng/dl). (b) Patients with normal recovery of total testosterone (X320 ng/dl). Discussion AA with LHRHa, in various clinical settings, has increasingly been used to treat prostate cancer. 2 7 Knowledge of hormone and PSA changes after cessation of AA is important for accurate interpretation of the impact of newly developed strategies for using this modality.
4 248 Table 3 PSA values after withdrawal of androgen ablation stratified by total testosterone recovery Total testosterone recovery (ng/dl) No. pts. (%) PSA range (ng/ml) Total o >10.1 o (24.1) 5 (71.4) 1 (14.3) 1 (14.3) X50.0 and o (37.9) 4 (36.4) 2 (18.2) 5 (45.5) X (37.9) 3 (27.3) 3 (27.3) 5 (45.5) No. pts., number of patients; PSA, prostate-specific antigen. Studies have suggested that recovery of T levels after short-term AA is relatively rapid. For example, Oefelein 11 reported a 6-month median duration of castrate level T (r20 ng/dl) after a single 3-month LHRHa injection. Similarly, Nejat et al 10 reported a median time from withdrawal to T normalization (4270 ng/dl) of 7 months following a median of 9 months of AA produced by 1- or 3-month depot LHRHa and antiandrogen. Recovery was often delayed, however, in the relatively small number of patients treated for X24 months. This was seen in the study of Nejat et al, although only seven of 68 patients underwent the longer-term treatment. Likewise, Hall et al 9 reported that 9 months after withdrawal, the median T values remained in the castrate range (o50 ng/dl) in 14 patients who had undergone an average of 38.6 (25 82) months of 3-month LHRHa depot therapy with or without antiandrogen. There was no correlation between duration of therapy and time course of T recovery. Following adjuvant AA of between 3 months and 3 years duration in patients undergoing definitive radiotherapy, Pickles et al 6 reported that 79% recovered normal T levels (10 nmol/l) and 93% recovered levels of at least 5 nmol/l. In multivariate analysis, advanced age, low pretherapy T and use of 3-month LHRHa were all significantly associated with delayed T recovery. Duration of AA was not significantly associated with time to T recovery, but only nine men had undergone AA for more than 2 y. We conducted a similar investigation using predominantly monthly LHRHa injections with or without antiandrogen. Testosterone levels in 10 patients from Group 1 (83%) and nine from Group 2 (35%) recovered to the normal range at a median time of 3.0 (2 9) months and 11.0 (2 19) months, respectively (Po0.01). In Group 2, the median T value was in the castrate range at 6 months, but recovered above this level at 9 months. This suggests that the time course of T recovery may differ between monthly and 3-month depot injections, since Hall et al 9 reported a more durable response with a 3-month depot preparation. Pickles et al 6 have suggested a switch from 3-month to monthly depot injections for the last year of adjuvant therapy to encourage prompt T recovery, and our findings support their suggestion. Although significant in univariate analysis, the duration of AA was not a significant independent predictor of delayed T recovery. This lack of significance may be due to the small number of patients in this study. Group 2 patients with more than 36 months of AA were not notably different from the rest of the group. This is in accord with the experience of Hall et al. 9 It seems that once AA duration reaches 24 months, further increases may have little impact on T recovery. Recovery of T paralleled LH levels in the majority of patients. Six of seven patients who had castrate T levels after at least 17 months off therapy had elevated levels of LH. All these had received LHRHa alone or with antiandrogen. Testosterone levels prior to AA had been normal in the two patients for whom they were available. Although it has been suggested that the effect of LHRHa on spermatogenesis and Leydig cell function may be reversible, 12,13 prolonged administration may lead to permanent impairment in at least some patients. However, as described by Pickles et al, 6 T recovery may occur in some patients after periods as long as 5 y. The level of LH was suppressed in our remaining patient with castrate T levels, who had been under DESD for 126 months. Long-term DESD may have affected the recovery of biological function in the hypothalamic pituitary testicular axis. The mechanism is not certain, but a similar observation with diethylstilbestrol has been reported. 14 Oefelein 8 suggested higher-than-castrate T levels as a threshold for resuming long-acting LHRHa therapy. Although this suggestion seems reasonable, the most appropriate threshold value of T remains to be determined. Although secretion and production of PSA are known to be under androgenic control, levels of PSA in our study did not always parallel T recovery (Figure 2, Table 3). Nejat et al 10 suggested caution in the interpretation of PSA levels in men with subnormal T. In this study, approximately one-third of patients with normal T had suppressed PSA levels (less than 1 ng/ml) after prolonged AA. This effect has been explained by altered expression of PSA by tumor cells following AA. 2 4 Host factors, including deferred recovery of free testosterone and sex hormone binding globulin, may be involved in those with the lowest total testosterone levels. 13,15 Clinically, this implies that interpretation of neoadjuvant and adjuvant endocrine therapy needs careful consideration and long-term follow-up. Our study is limited by its nonrandomized nature and the small number of patients. The number of patients with subnormal T prior to AA, which is known to occur in some elderly men, 16 is unknown in this study but is also lacking in all previous studies It is also unknown whether our current findings may be applicable to other races. The interpretation of our current findings thus needs caution and careful consideration. Further work is warranted. Conclusions Recovery of T levels is delayed in a substantial number of patients when the duration of AA exceeds 24 months. More information, including certain host factors, is needed to interpret correctly PSA changes in various clinical settings.
5 Acknowledgements We thank WA Thomasson, PhD, for expert editorial assistance. This work was supported in part by a Grant from the Ministry of Health and Welfare of Japan and the Foundation for Promotion of Cancer Research in Japan. References 1 Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: Egawa S et al. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. Jpn J Clin Oncol 2000; 30: Akakura K et al. Effects of intermittent androgen suppression on androgen-dependent tumours: apoptosis and serum prostate specific antigen. Cancer 1993; 71: Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Intermittent androgen suppression: rationale and clinical experience. In: Schroder T-H. (ed). Recent Advances in Prostate Cancer and BPH. Parthenon: New York, 1997, pp Moul JW. Contemporary hormonal management of advanced prostate cancer. Oncology 1998; 12: Pickles T et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 2002; 94: Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: Oefelein MG. Serum testosterone-based luteinizing hormonereleasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 1999; 54: Hall MC et al. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999; 53: Nejat RJ et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. JUrol2000; 164: Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. JUrol1998; 160: Kuber W, Viehberger G, Zeillinger R, Spona J. Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI ) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer. Urol Res 1991; 19: Lunglmayr G et al. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urol Res 1988; 16: Tomic B, Bergman B. Hormonal effects of cessation of estrogen treatment for prostatic carcinoma. J Urol 1987; 138: Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? JUrol2000; 163: Vermeulen A, Kaufman JM. Ageing of the hypothalamopituitary-testicular axis in men. Horm Res 1995; 43:
Maximal androgen blockade versus castration alone in patients with metastatic prostate cancer*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-0037-9 September 2014, Vol. 13, No. 9, P417 P421 Maximal androgen blockade versus castration alone in patients with metastatic prostate cancer* Abeer
More informationMetastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationFactors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
Original Article - Urological Oncology Investig Clin Urol 218;59:18-24. https://doi.org/1.4111/icu.218.59.1.18 pissn 2466-493 eissn 2466-54X Factors associated with testosterone recovery after androgen
More informationManipulating Hormones: Androgen Suppression in Prostate Cancer Patients
Focus on CME at the University of Queen s ManitobaUniversity Manipulating Hormones: Androgen Suppression in ostate Cancer Patients By D. Robert Siemens, MD, FRCSC Case A 62-year old man presents with complaints
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationIntermittent Androgen Suppression as a Treatment for Prostate Cancer: A Review
Intermittent Androgen Suppression as a Treatment for Prostate Cancer: A Review ANDREW M. EVENS, TIMOTHY M. LESTINGI, JACOB D. BITRAN Department of Medicine, Division of Hematology/Oncology, Lutheran General
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More information2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationThe Clinical Potential of Pretreatment Serum Testosterone Level to Improve the Efficiency of Prostate Cancer Screening
european urology 51 (2007) 375 380 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Clinical Potential of Pretreatment Serum Testosterone Level to Improve
More informationMedical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
ORIGINAL PAPER DOI: 10.4081/aiua.2017.4.282 Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels? Murat Bagcioglu
More informationCombined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer
Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival Hideyuki Akaza, MD 1 ; Shiro Hinotsu, MD 2 ; Michiyuki
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationSix-Month Depot Formulation of an LHRH agonist for the Treatment of Advanced Prostate Cancer Efficacy and Tolerability
Original article 2015 Journal of Medical Drug Reviews. All rights reserved. J Med Drug Rev 2015;5:33 38 Six-Month Depot Formulation of an LHRH agonist for the Treatment of Advanced Prostate Cancer Efficacy
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationHormonotherapy of advanced prostate cancer
Annals of Oncology 16 (Supplement 4): iv80 iv84, 2005 doi:10.1093/annonc/mdi913 Hormonotherapy of advanced prostate cancer P. Pronzato & M. Rondini Department of Oncology, Felettino Hospital, La Spezia,
More informationreviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy
reviews therapy LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate Martin I. Resnick, MD, Lester Persky Professor and Chief, Department of Urology, Case Western Reserve University School
More informationProstate Cancer Case Study 2. Medical Student Case-Based Learning
Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationresponse of PCa to testosterone deprivation in the early 1940s, testosterone has been considered as fuel to the fire of PCa.
BJUI BJU INTERNATIONAL Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment Eduardo Garc í a-cruz, Marta Piqueras, Jorge Huguet, Lluis Peri, Laura
More informationPCa Commentary. Volume 79 May June 2014
1221 Madison Street, 1 st Floor Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 79 May June 2014 CONTENT: Active Surveillance Page 1 Firmagon and Lupron Page 5 ACTIVE SURVEILLANCE:
More informationIntermittent Androgen Suppression - A standard of care or a good second choice?
Intermittent Androgen Suppression - A standard of care or a good second choice? Dr Nicholas Buchan Uro-oncology Fellow Olympic Medal Standings Gold Silver Bronze USA 9 15 13 Germany 10 13 7 Canada 14 7
More informationRadiotherapy for Localized Hormone-refractory Prostate Cancer in Japan
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:
Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationProstate cancer is now the most
: a new hormonal treatment for prostate cancer Professor Malcolm Mason, School of Medicine, Cardiff University, Velindre Hospital, Whitchurch, Cardiff - hypothalamus According to NICE, prostate cancer
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationAppropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?
European Urology Supplements European Urology Supplements 4 (2005) 14 19 Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B.
More informationLuteinising hormone-releasing hormone (LHRH) agonists in prostate cancer
B88 April 2015 2.1 Community Interest Company Luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer This bulletin focuses on luteinising hormone-releasing hormone (LHRH) agonists. Currently
More informationMOLECULAR AND CLINICAL ONCOLOGY 4: , 2016
MOLECULAR AND CLINICAL ONCOLOGY 4: 839-844, 2016 Clinical outcomes of anti androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial
More informationRadiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationeuropean urology 50 (2006)
european urology 50 (2006) 483 489 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Duration of Testosterone Suppression after a 9.45 mg Implant of the GnRH-Analogue
More informationMiyazawa et al. Basic and Clinical Andrology (2015) 25:7 DOI /s
Miyazawa et al. Basic and Clinical Andrology (2015) 25:7 DOI 10.1186/s12610-015-0023-2 RESEARCH ARTICLE Open Access Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationThis is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/103187/ This is the author s version of a work that was submitted to / accepted
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationUnrecognized Kinetics of Serum Testosterone: Impact on Short- Term Androgen Deprivation Therapy for Prostate Cancer
Original Article http://dx.doi.org/10.3349/ymj.2014.55.3.570 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 55(3):570-575, 2014 Unrecognized Kinetics of Serum Testosterone: Impact on Short- Term Androgen
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationThe Current State of Hormonal Therapy for Prostate Cancer
The Current State of Hormonal Therapy for Prostate Cancer The Current State of Hormonal Therapy for Prostate Cancer Beth A. Hellerstedt, MD; Kenneth J. Pienta, MD Dr. Hellerstedt is Fellow, Division of
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationClinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:
Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following
More informationIntroduction. In patients with prostate cancer, disease progression can have serious clinical consequences, such as painful bone
(2005) 8, 194 200 & 2005 Nature Publishing Group All rights reserved 1365-7852/05 $30.00 www.nature.com/pcan Bicalutamide ( Casodex ) 150 mg in addition to standard care in patients with nonmetastatic
More informationAndrogen deprivation therapy: New concepts. Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto
Androgen deprivation therapy: New concepts Laurence Klotz Professor of Surgery Sunnybrook HSC University of Toronto Clinical Research funding: 1. Bayer/Algeta 2. Ferring 3. Abbott 4. GSK 5. EMD Serono
More informationRisk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
More informationNEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING
NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING RADICAL PROSTATECTOMY IN PATIENTS WITH STAGE T2 PROSTATIC CANCER Takeshi Uedal, Hiroomi Nakatsul, Shigeo Isaka2 and Jun Shimazaki2 1Urology, Kumagaya
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationDoes TRT Induce Prostate Cancer?
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
More informationEVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER
EVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER Abraham Morgentaler, MD Director and Founder Men s Health Boston Associate Clinical Professor Harvard Medical School And the Urology
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationPACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin)
ONC.000-092-861.10.0 PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG (goserelin) Name of the medicinal product Zoladex LA 10.8mg depot Qualitative and quantitative composition Goserelin acetate (equivalent to 10.8
More informationNaviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
More informationTestosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More informationand Sayo Suda Takeshi Kashiwabara *
Kashiwabara and Suda BMC Cancer (2018) 18:619 https://doi.org/10.1186/s12885-018-4541-0 RESEARCH ARTICLE Open Access Usefulness of combined androgen blockade therapy with gonadotropinreleasing hormone
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationFrancesco Bertoldo. Metabolic Bone Diseases and Osteoncology Unit DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY
DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY Francesco Bertoldo Metabolic Bone Diseases and Osteoncology Unit Department of Medicine University di Verona EPIDEMIOLGY OF PROSTATE CANCER Prostate
More informationEligard W 6: A New Form of Treatment for Prostate Cancer
european urology supplements 5 (2006) 905 910 available at www.sciencedirect.com journal homepage: www.europeanurology.com Eligard W 6: A New Form of Treatment for Prostate Cancer Oliver Sartor * Dana
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationERLEADA (apalutamide) oral tablet
ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationAndrogen Deprivation Therapy A Question of Timing
Androgen Deprivation Therapy A Question of Timing James Johnston BSc MBChB FRACS (Urol) Disclosure 1 OUTLINE History Watchful waiting Node positive patient Recurrence Intermittent Androgen Suppression
More informationReview of Polish and international guidelines on hormonal therapy in localized prostate cancer
Review article NOWOTWORY Journal of Oncology 2016, volume 66, number 5, 403 407 DOI: 10.5603/NJO.2016.0071 Polskie Towarzystwo Onkologiczne ISSN 0029 540X www.nowotwory.edu.pl Review of Polish and international
More informationA comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients
ONCOLOGY LETTERS 14: 299-305, 2017 A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients KOICHI SHOJI 1, JUN TEISHIMA 1, TETSUTARO
More informationmajority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival.
Hello. I am Farshid Dayyani. I am Assistant Professor in Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. We will be talking today about prostate cancer for survivorship
More informationMedical Treatments for Prostate Cancer
Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationThe New England Journal of Medicine BILATERAL ORCHIECTOMY WITH OR WITHOUT FLUTAMIDE FOR METASTATIC PROSTATE CANCER
BILATERAL ORCHIECTOMY WITH OR WITHOUT FLUTAMIDE FOR METASTATIC PROSTATE CANCER MARIO A. EISENBERGER, M.D., BRENT A. BLUMENSTEIN, PH.D., E. DAVID CRAWFORD, M.D., GARY MILLER, M.D., PH.D., DAVID G. MCLEOD,
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationClinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists
original research research research Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists Jun Kawakami, MD, FRCSC; * Alvaro Morales, MD, FRCSC, OC *Department
More informationFinal Appraisal Report. Ferring Pharmaceuticals Ltd. Advice No: 2109 December Recommendation of AWMSG
Final Appraisal Report Degarelix (Firmagon ) for the treatment of advanced hormone-dependent prostate cancer Ferring Pharmaceuticals Ltd Advice No: 2109 December 2009 Recommendation of AWMSG Degarelix
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationINTRODUCTION PATIENTS AND METHODS. Jpn J Clin Oncol 2007;37(10) doi: /jjco/hym098
Jpn J Clin Oncol 2007;37(10)775 781 doi:10.1093/jjco/hym098 Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected
More informationDegarelix Subcutaneous Injection (Firmagon ) Treatment Guideline
Mid Essex Locality Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline Contents FlowChart 2 Summary... 3 Key points... 3 Introduction... 3 Pharmacology... 3 Product information... 4 Place
More informationHow Should WeTreat Patients with Locally Advanced Prostate Cancer?
European Urology Supplements European Urology Supplements 2 (2003) 14 22 How Should WeTreat Patients with Locally Advanced Prostate Cancer? Malcolm Mason * Section of Oncology and Palliative Medicine,
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationEdward P. Gelmann, MD
Prostate Cancer Edward P. Gelmann, MD Prostate Cancer Etiology and Ep pidemiology Screening Pathology Staging Localized Disease Metastatic Disease normal prostate epithelium GSTP1 CpG island hypermethylation
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationTreatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationNEW ZEALAND DATA SHEET
1 NEW ZEALAND DATA SHEET NAME OF MEDICINE ZOLADEX 10.8 mg Goserelin (present as goserelin acetate) 10.8 mg injection. PRESENTATION A sterile, white to cream coloured cylindrical depot in which goserelin
More informationIntroduction. Macclesfield, Cheshire, UK; and 4 AstraZeneca, Wilmington, Deleware, USA
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole D Saltzstein 1 *, P Sieber 2, T Morris 3 &
More information